Skip to content

Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma

Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02613156
Enrollment
25
Registered
2015-11-24
Start date
2014-06-30
Completion date
2015-10-31
Last updated
2016-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Hepatocellular Carcinoma

Keywords

laparoscopic, hepatocellular carcinoma, recurrence

Brief summary

This study is aiming to evaluate the clinical efficacy of complete laparoscopic resection of recurrent hepatocellular carcinoma (HCC).

Detailed description

The investigators conducted a prospective study of 64 patients who were diagnosed with recurrent HCC and underwent surgical resection at the Sun Yat-sen University Cancer Center from June 2014 to November 2014; 31 patients were enrolled in the laparoscopic group and underwent complete laparoscopic resection of HCC, and 33 patients were enrolled in the control group and underwent open surgical resection. The operation time, intraoperative blood loss, shortest distance between the tumor edge and normal liver tissue, postoperative pain scores, postoperative time until the patient could walk, postoperative time until the patient could pass gas, hospital stay, and inpatient costs were compared between the two groups. The patients were followed up for one year after surgery, and the relapse-free survival was compared between the two groups.

Interventions

The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson & Johnson, USA), a laparoscopic linear cutter stapler (Johnson & Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. recurrent HCC after open surgery 2. recurrent HCC located in any part of the left lateral lobe or the diaphragm side of the right lobe and near the surface of the liver, which resulted in an easier operation 3. no significant surgical contraindications 4. no major vessel or bile duct tumor invasion and metastasis 5. grade A or B liver function or grade C liver function that recovered to grade A after liver-protective treatment; 6. the patient and his/her family was willing to undergo laparoscopic resection.

Exclusion criteria

1. major vessel or bile duct tumor invasion 2. recurrent HCC located in the right liver parenchyma and near secondary vessels and bile ducts, resulting in a difficult operation 3. grade C liver function 4. significant surgical contraindications 5. the patient and his/her family declined laparoscopic hepatectomy.

Design outcomes

Primary

MeasureTime frameDescription
Perioperative complicationswithin the first 30 daysThe operation time, intraoperative blood loss, shortest distance between the tumor edge and normal liver tissue, postoperative pain scores, postoperative time until the patient could walk, postoperative time until the patient could pass gas, hospital stay, and inpatient costs were compared between the two groups.

Secondary

MeasureTime frameDescription
relapse-free survival1 year after surgeryThe patients were followed up for one year after surgery, and the relapse-free survival was compared between the two groups.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026